Pfizer-J&J Alzheimer’s Drug Shows Promise for Early Use

Johnson & Johnson and Pfizer Inc.’s bapineuzumab, an experimental drug that failed to help Alzheimer’s symptoms in a study, showed signs of reducing physical damage in the brain, according to a deeper analysis.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.